Clinical Trials Logo

Clinical Trial Summary

Due to brain damage acquired (BDA), is often difficulty in gait and balance alterations, as problems that patients designated as the most disabling. It is essential to an effective assessment of the balance. Objective: The purpose of the present project adapt and verify the validity of the scale MiniBESTest, version of the BESTest, in patients with BDA in subacute and chronic stage, since that is postulated as a brief tool and covering the peculiarities of the specific alterations of the patient after suffering brain damage. Methodology: Between September 2019 and December 2020 will be transcultural adaptation to the BDA and validation of psychometric scale Mini-BESTest in three phases. 60 subjects who receive treatment in the center of attention State reference to brain damage (CEADAC), together with the comunidad de Madrid private neurological rehabilitation centers will be recruited. Results: validity and reliability parameters shall be calculated by means of descriptive statistics for each item of the scales and the set of scale score. You will also analyze the internal consistency using Cronbach's alpha, the interclass correlation coefficient will be used to determine the reliability, and the items will be scanned with the Pearson coefficient: > 0.20, among other parameters.


Clinical Trial Description

Marta Fernández Hontoria, physiotherapist at the State Reference Center of Attention to Brain Injury (CEADAC), will develop, together with her team formed by Cristina Lirio Romero and María Torres Lacomba of the Department of Physiotherapy at the University of Alcalá, a cross-cultural adaptation to the Spanish population with Adquired Brain Injury (ABI) and psychometric validation of the Mini-BESTest scale. Previously, the author of the scale has been asked for consent. The study will take place at the CEADAC. After receiving the approval of the Ethics and Clinical Research Committee of the University of Alcalá (Madrid), it is proposed to implement the study between September 2019 and May 2020. A minimum of 100 adults, aged between 18 and 65, will be recruited subacute or chronic state after suffering brain damage. The sample size conforms to COSMIN recommendations. After verifying that there are no parallel studies on the subject in progress, the possible participants will be informed of the development of the investigation (ANNEX 1), who must sign the informed consent (ANNEX 2) before being recruited into the study. In addition, a coding sheet (ANNEX 3) of the participants will be filled in so that from now on the data related to the proper name does not appear but with a number that ensures the protection of their data. The participants will be all users of CEADAC and the selection criteria to enter to participate in the study will be: adults who had suffered a ABI at least 2 months ago, that their disability before suffering it was less than or equal to three on the scale modified by Rankin, who have an absence of cognitive impairment according to the Minimental State Examination scale, that is, a score in it greater than 24, without previous diseases that alter the balance, that were clinically stable and without fever, with the ability to walk with help technical or without it, and that they gave their informed consent. On the other hand, those people with medical contraindications for physical tests (acute musculoskeletal or peripheral nervous system disorders), who did not understand the instructions, severe aphasias or with subjects with acute processes of any added pathology will be excluded. The study was developed in 3 phases: Phase 1: Transcultural adaptation process. Phase 2: Pre-Test: collected , as well as the ease of interpretation of the results. Phase 3: Psychometric validation process. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04052087
Study type Observational [Patient Registry]
Source Centro de Referencia Estatal de Atención Al Daño Cerebral
Contact
Status Completed
Phase
Start date March 15, 2021
Completion date June 30, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Recruiting NCT05134116 - SafeBoosC III Two-year Follow-up
Completed NCT03712839 - Cognitive-functional Evaluation of Anosognosia
Completed NCT03958487 - An Executive/Monitoring Treatment Protocol on Everyday Life Activities N/A
Recruiting NCT06083233 - Role of Brain Specific Biomarkers in Hydrocephalus N/A
Recruiting NCT05692804 - Evaluation of Neuronal Damage in Patients Undergoing Robot-assisted Laparoscopic Radical Prostatectomy With Biomarkers
Recruiting NCT06027645 - Early Intervention Based on Neonatal Crawling in Very Premature Infants at Risk For Neurodevelopmental Disorder N/A
Completed NCT01076257 - Efficacy of Modified Constraint-induced Movement Therapy in Children With Brain Damage N/A
Recruiting NCT03191409 - Interaction Research on Cognitive Impairment and Emotional Disorder in End-stage Renal Disease N/A
Completed NCT03823430 - Pupillometry : Predictive Indicator in External Ventricular Drain Clamping ?
Enrolling by invitation NCT05864677 - Cerebrolysin in Prevention of Postoperative Delirium in Cardiac Surgery N/A
Completed NCT04368052 - Liver Transplant Does it Affect the Brain N/A
Completed NCT04419818 - A Neuropsychological Test Battery for the Assessment of Time Deficits
Completed NCT04373837 - Rehabilitation Treatment of Time Deficits in Brain-damaged Patients N/A
Recruiting NCT05399602 - The Role of Neurofilament Light (NfL) in Patients With Hydrocephalus N/A
Terminated NCT03827421 - Junior Emergency Physician Learning Curve to Perform Transcranial Doppler on Brain-damage Patients
Recruiting NCT03344731 - Cognitive Abilities in Brain Damaged Patients N/A
Completed NCT04846738 - Transcranial Doppler and Quantitative Pupillometry as Neurological Prognostic Factors in Brain Damaged Patients Admitted to Intensive Care Unit